Identifying tumor antigens and immune subtypes of gastrointestinal MALT lymphoma for immunotherapy development
MALT lymphoma is an extranodal B-cell lymphoma of the marginal zone of mucosa-associated lymphoid tissue (MALT), caused by malignant transformation of B-cells in the marginal zone. In this work, we aim to explore the potential relationship between MALT lymphoma and DLBCL. Vaccines derived from messe...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-12-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.1060496/full |
| _version_ | 1811300758615752704 |
|---|---|
| author | Xinlu Jiang Huanhuan Zhang Jinju Ni Xu Zhang Kaiyang Ding |
| author_facet | Xinlu Jiang Huanhuan Zhang Jinju Ni Xu Zhang Kaiyang Ding |
| author_sort | Xinlu Jiang |
| collection | DOAJ |
| description | MALT lymphoma is an extranodal B-cell lymphoma of the marginal zone of mucosa-associated lymphoid tissue (MALT), caused by malignant transformation of B-cells in the marginal zone. In this work, we aim to explore the potential relationship between MALT lymphoma and DLBCL. Vaccines derived from messenger ribonucleic acid (mRNA) may provide satisfactory results. Despite being a promising treatment option, immunotherapy isn’t widely used in treating renal cell carcinoma, as only a few patients respond to the treatment. The Cancer Genome Atlas (TCGA) analysis revealed gene expression profiles and clinical information. Antigen-presenting cells infiltrated the immune system using TIMER tool (http://timer.cistrome.org/). GDSC (Genomics of Drug Sensitivity in Cancer) data were used to estimate drug sensitivity. Immune-related genes were associated with a better prognosis in MALT lymphoma patients and higher levels of antigen-presenting cells. There is a significant relationship between these immune subtypes and immunological checkpoints, immunogenic cell death regulators, and prognostic variables for MALT lymphoma patients. In this study, we provide a theoretical foundation for the development of mRNA vaccines and suggest that KLHL14 could potentially be used as antigens to develop mRNA vaccines for MALT lymphoma. |
| first_indexed | 2024-04-13T06:56:12Z |
| format | Article |
| id | doaj.art-b253e90fe24849ae8bbca16c511ab2d9 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-13T06:56:12Z |
| publishDate | 2022-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-b253e90fe24849ae8bbca16c511ab2d92022-12-22T02:57:14ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2022-12-011210.3389/fonc.2022.10604961060496Identifying tumor antigens and immune subtypes of gastrointestinal MALT lymphoma for immunotherapy developmentXinlu Jiang0Huanhuan Zhang1Jinju Ni2Xu Zhang3Kaiyang Ding4Department of Hematology, Anhui Provincial Hospital Affiliated to Anhui Medical University, Hefei, Anhui, ChinaDepartment of Respiratory, Wannan Medical College, Wuhu, Anhui, ChinaDepartment of Hematology, Anhui Provincial Hospital Affiliated to Anhui Medical University, Hefei, Anhui, ChinaDepartment of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, ChinaDepartment of Hematology, Anhui Provincial Hospital Affiliated to Anhui Medical University, Hefei, Anhui, ChinaMALT lymphoma is an extranodal B-cell lymphoma of the marginal zone of mucosa-associated lymphoid tissue (MALT), caused by malignant transformation of B-cells in the marginal zone. In this work, we aim to explore the potential relationship between MALT lymphoma and DLBCL. Vaccines derived from messenger ribonucleic acid (mRNA) may provide satisfactory results. Despite being a promising treatment option, immunotherapy isn’t widely used in treating renal cell carcinoma, as only a few patients respond to the treatment. The Cancer Genome Atlas (TCGA) analysis revealed gene expression profiles and clinical information. Antigen-presenting cells infiltrated the immune system using TIMER tool (http://timer.cistrome.org/). GDSC (Genomics of Drug Sensitivity in Cancer) data were used to estimate drug sensitivity. Immune-related genes were associated with a better prognosis in MALT lymphoma patients and higher levels of antigen-presenting cells. There is a significant relationship between these immune subtypes and immunological checkpoints, immunogenic cell death regulators, and prognostic variables for MALT lymphoma patients. In this study, we provide a theoretical foundation for the development of mRNA vaccines and suggest that KLHL14 could potentially be used as antigens to develop mRNA vaccines for MALT lymphoma.https://www.frontiersin.org/articles/10.3389/fonc.2022.1060496/fullgastrointestinal MALT lymphomaprognostic factorsKLHL14mRNA vaccinesdrugs target |
| spellingShingle | Xinlu Jiang Huanhuan Zhang Jinju Ni Xu Zhang Kaiyang Ding Identifying tumor antigens and immune subtypes of gastrointestinal MALT lymphoma for immunotherapy development Frontiers in Oncology gastrointestinal MALT lymphoma prognostic factors KLHL14 mRNA vaccines drugs target |
| title | Identifying tumor antigens and immune subtypes of gastrointestinal MALT lymphoma for immunotherapy development |
| title_full | Identifying tumor antigens and immune subtypes of gastrointestinal MALT lymphoma for immunotherapy development |
| title_fullStr | Identifying tumor antigens and immune subtypes of gastrointestinal MALT lymphoma for immunotherapy development |
| title_full_unstemmed | Identifying tumor antigens and immune subtypes of gastrointestinal MALT lymphoma for immunotherapy development |
| title_short | Identifying tumor antigens and immune subtypes of gastrointestinal MALT lymphoma for immunotherapy development |
| title_sort | identifying tumor antigens and immune subtypes of gastrointestinal malt lymphoma for immunotherapy development |
| topic | gastrointestinal MALT lymphoma prognostic factors KLHL14 mRNA vaccines drugs target |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2022.1060496/full |
| work_keys_str_mv | AT xinlujiang identifyingtumorantigensandimmunesubtypesofgastrointestinalmaltlymphomaforimmunotherapydevelopment AT huanhuanzhang identifyingtumorantigensandimmunesubtypesofgastrointestinalmaltlymphomaforimmunotherapydevelopment AT jinjuni identifyingtumorantigensandimmunesubtypesofgastrointestinalmaltlymphomaforimmunotherapydevelopment AT xuzhang identifyingtumorantigensandimmunesubtypesofgastrointestinalmaltlymphomaforimmunotherapydevelopment AT kaiyangding identifyingtumorantigensandimmunesubtypesofgastrointestinalmaltlymphomaforimmunotherapydevelopment |